Novo Nordisk Shares Outstanding 2010-2024 | NVO
Novo Nordisk shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Novo Nordisk shares outstanding for the quarter ending September 30, 2024 were 4.461B, a 0.63% decline year-over-year.
- Novo Nordisk 2023 shares outstanding were 4.495B, a 1.1% decline from 2022.
- Novo Nordisk 2022 shares outstanding were 4.545B, a 1.31% decline from 2021.
- Novo Nordisk 2021 shares outstanding were 4.605B, a 1.6% decline from 2020.
Novo Nordisk Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
4,495 |
| 2022 |
4,545 |
| 2021 |
4,605 |
| 2020 |
4,680 |
| 2019 |
4,757 |
| 2018 |
4,849 |
| 2017 |
4,956 |
| 2016 |
5,069 |
| 2015 |
5,155 |
| 2014 |
5,260 |
| 2013 |
5,387 |
| 2012 |
5,517 |
| 2011 |
5,701 |
| 2010 |
5,855 |
| 2009 |
5,992 |
Novo Nordisk Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
4,461 |
| 2024-06-30 |
4,465 |
| 2024-03-31 |
4,471 |
| 2023-12-31 |
4,495 |
| 2023-09-30 |
4,489 |
| 2023-06-30 |
4,503 |
| 2023-03-31 |
4,513 |
| 2022-12-31 |
4,545 |
| 2022-09-30 |
4,537 |
| 2022-06-30 |
4,545 |
| 2022-03-31 |
5,762 |
| 2021-12-31 |
4,605 |
| 2021-09-30 |
4,595 |
| 2021-06-30 |
4,610 |
| 2021-03-31 |
4,632 |
| 2020-12-31 |
4,680 |
| 2020-09-30 |
4,670 |
| 2020-06-30 |
4,691 |
| 2020-03-31 |
4,710 |
| 2019-12-31 |
4,757 |
| 2019-09-30 |
4,746 |
| 2019-06-30 |
4,767 |
| 2019-03-31 |
4,789 |
| 2018-12-31 |
4,849 |
| 2018-09-30 |
4,838 |
| 2018-06-30 |
4,862 |
| 2018-03-31 |
4,885 |
| 2017-12-31 |
4,956 |
| 2017-09-30 |
4,939 |
| 2017-06-30 |
4,968 |
| 2017-03-31 |
5,000 |
| 2016-12-31 |
5,069 |
| 2016-09-30 |
5,062 |
| 2016-06-30 |
5,082 |
| 2016-03-31 |
5,100 |
| 2015-12-31 |
5,155 |
| 2015-09-30 |
5,144 |
| 2015-06-30 |
5,168 |
| 2015-03-31 |
5,208 |
| 2014-12-31 |
5,260 |
| 2014-09-30 |
5,244 |
| 2014-06-30 |
5,275 |
| 2014-03-31 |
5,306 |
| 2013-12-31 |
5,387 |
| 2013-09-30 |
5,363 |
| 2013-06-30 |
5,405 |
| 2013-03-31 |
5,447 |
| 2012-12-31 |
5,517 |
| 2012-09-30 |
5,478 |
| 2012-06-30 |
5,524 |
| 2012-03-31 |
5,605 |
| 2011-12-31 |
5,619 |
| 2011-09-30 |
5,681 |
| 2011-06-30 |
5,738 |
| 2011-03-31 |
5,767 |
| 2010-12-31 |
5,775 |
| 2010-09-30 |
5,823 |
| 2010-06-30 |
5,889 |
| 2010-03-31 |
5,930 |
| 2009-12-31 |
5,952 |
| 2009-09-30 |
6,014 |
| 2009-06-30 |
6,030 |
| 2009-03-31 |
6,127 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$464.190B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
